Subscribe to Search results

PFC heat treated products for 24 hours (extended from 2 hours).

Published on:

PFC experienced issues with the freeze drying process in relation to the production of Z8.

Published on:

Clinical trials of Z8 were delayed due to a question about compensation to patients who might be harmed during the trials raised by Prof Ludlam, supported by all of Scotland's haemophilia doctors.

Published on:

Dr Peter Foster was head of the R&D Department of the SNBTS PFC.

Published on:

Dr Peter Foster was a biochemist at PFC.

Published on:

A H Woodhead wrote to all Blood Transfusion Service directors about a batch of Factorate recalled by Armour Pharmaceuticals.

Published on:

The Committee on Safety of Medicines reviewed Dr Peter Jones' letter regarding AIDS and the heat treatment of clotting factor and advised that there was insufficient evidence for action to be taken on any specific product.

Published on:

Dr Jones apologised to the DHSS for making public his statement about heat-treated Factor 8 being unsafe.

Published on:

The CBLA agreed to finance the trial of 8CRV.

Published on:

Dr Brian Colvin thought that it would be more problematic if the heat-treated commercial products turned out to be unsafe from HIV.

Published on:

The Krever Inquiry found that Armour should have informed the Canadian Bureau of Biologics about Dr Prince's findings, but chose not to.

Published on:

Contrary to the findings of the Krever Inquiry, Justice Benotto, in a subsequent Canadian criminal case in 2007, found that it would have been unreasonable and irresponsible for Armour to have thrust Prince's studies into the community in a time of great uncertainty.

Published on:

The Northern Regional Health Authority's position on funding additional cost was yet to be declared.

Published on:

Armour Pharmaceutical Company Limited in the UK was incorporated in 1959. It had several changes in name and parent company and was dissolved in 2010.

Published on:

From mid March 1985 Cutter had taken the strategic decision to stop selling unheated stock to UK centres.

Published on:

An internal report of Cutter speaking of the UK sales position recorded that a small "short dated batch" of non-heat-treated concentrate was sold during the previous month.

Published on:

An inventory for Alpha UK showed that just under 25% of its current stocks remained non-heat-treated at the start of September 1985.

Published on:

The response by UK doctors to steps taken in the US was mixed. Dr Harris reported that Dr Rotblat "had been summoned to the Chief Medical Officer of the DHSS to answer questions concerning our product recall and discussions held in March concerning potential problems with Armour Factorate HT."

Published on:

Cutter had shown a hepatitis rate from heat treated products of 20% in "virgin or near-virgin" patients in studies in Bonn and Freiburg, and Hyland had a rate of 80% in a multi-centre study conducted by Dr Pier Mannucci.

Published on:

The first batch of Cutter product, Koate HT, which was made from 100% tested plasma was shipped to the UK in January/February 1986.

Published on: